Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results, Beats Expectations By $0.29 EPS

06 May 2026, 16:06 by Doug Wharley · The Cerbat Gem

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.29, FiscalAI reports. The company had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 28.38%. The firm’s revenue was up 55.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.47) EPS.

Here are the key takeaways from Travere Therapeutics’ conference call:

First FDA approval for Filspari in FSGS — establishes Filspari as the first and only approved medicine for FSGS, expanding the U.S. addressable population (company cites >30,000 FSGS patients and >100,000 across IgAN/FSGS) and underpinning a stated ~$3 billion potential peak sales opportunity.
Strong commercial momentum with record demand in IgA nephropathy (993 new patient start forms in Q1) and Filspari U.S. revenue of $105.2 million (≈88% YoY growth), plus early signs of faster uptake and initial payer approvals in the FSGS launch.
Pipeline progress on pegtibatinase — enrollment has restarted in the pivotal Phase III HARMONY study and the first post-restart patient was dosed, with top-line results expected in the second half of 2027 and the program positioned as a potential first disease-modifying therapy for classical HCU (addressable ~7,000–10,000 globally).
Operating costs and certain non-cash expenses rose meaningfully (R&D $57.1M; SG&A $80.3M; royalty expense $24.8M), the GAAP net loss was $37.1M (non‑GAAP net income $4.1M), and the company disclosed cash, marketable securities and receivables of ≈$352M (cash ≈$264.7M), which investors may watch closely given increased investment for launches and the Phase III program.

Travere Therapeutics Trading Down 0.2%

Shares of NASDAQ TVTX traded down $0.10 during trading on Wednesday, reaching $44.70. The company had a trading volume of 1,712,783 shares, compared to its average volume of 2,157,077. The company’s fifty day moving average price is $32.31 and its 200-day moving average price is $32.71. Travere Therapeutics has a 12 month low of $13.88 and a 12 month high of $48.61. The stock has a market cap of $4.13 billion, a P/E ratio of -194.33 and a beta of 1.13. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

Positive Sentiment: Wells Fargo raised its price target to $50 and upgraded TVTX to “Overweight,” giving the stock fresh upside from current levels. Wells Fargo Price Target Raise
Positive Sentiment: TD Cowen lifted its target sharply to $60 and maintained a “Buy” — another bullish analyst action that supports upside expectations tied to Travere’s pipeline and commercial execution. TD Cowen Price Target Raise
Positive Sentiment: Q1 results showed an EPS beat (reported $0.05 vs. consensus -$0.24) and management highlighted FILSPARI approval in FSGS, strong demand and progress on pegtibatinase — positives for revenue growth and long‑term value if commercial momentum continues. Q1 Results & Corporate Update
Neutral Sentiment: HC Wainwright reiterated a “Buy” and long‑term EPS runway (FY2027–FY2030 forecasts show multi‑year growth), supporting the bullish thesis despite small model adjustments. HC Wainwright Estimates
Neutral Sentiment: Investors can review the Q1 earnings call transcript for management commentary on commercial traction and pipeline timelines. Earnings Call Transcript
Negative Sentiment: Revenue missed expectations ($127.2M reported vs. ~$136.2M consensus) and some outlets flagged a quarterly loss/miss on revenue — a near‑term headwind that likely pressured the stock despite the EPS beat. Revenue Miss Coverage
Negative Sentiment: HC Wainwright trimmed FY2027–FY2030 EPS estimates slightly (minor cuts across years). While small, these revisions reduce near‑term model momentum and may temper upside expectations. HC Wainwright Estimate Revisions
Negative Sentiment: Director Roy Baynes sold 9,750 shares under a pre‑arranged 10b5‑1 plan (filed with the SEC); insider sales can be viewed negatively by some investors, even if pre‑planned. SEC Filing: Insider Sale

Insider Activity at Travere Therapeutics

In related news, CEO Eric M. Dube sold 64,000 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $41.09, for a total value of $2,629,760.00. Following the transaction, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at $17,787,285.74. The trade was a 12.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 9,100 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $39.09, for a total value of $355,719.00. Following the completion of the sale, the insider owned 113,987 shares in the company, valued at $4,455,751.83. The trade was a 7.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 310,852 shares of company stock valued at $11,890,666 over the last ninety days. Insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently bought and sold shares of TVTX. State of Wyoming bought a new stake in Travere Therapeutics during the fourth quarter valued at $37,000. Smartleaf Asset Management LLC raised its position in shares of Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after acquiring an additional 487 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at about $33,000. Empowered Funds LLC acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at about $115,000. Finally, Parallel Advisors LLC boosted its position in shares of Travere Therapeutics by 384.0% during the 4th quarter. Parallel Advisors LLC now owns 3,785 shares of the company’s stock valued at $145,000 after purchasing an additional 3,003 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently weighed in on TVTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. HC Wainwright increased their target price on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday. TD Cowen lifted their price target on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Wedbush lifted their target price on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.83.

Get Our Latest Research Report on Travere Therapeutics

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.